braftovi
pierre fabre medicament - encorafenib - melanoma; colorectal neoplasms - daganatellenes szerek - encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, who have received prior systemic therapy.
mektovi
pierre fabre medicament - binimetinib - melanóma - daganatellenes szerek - binimetinib kombinálva encorafenib kezelésére javallt felnőtt betegek inoperábilis vagy áttétes melanoma a braf mutáció v600.
sorafenib accord
accord healthcare s.l.u. - sorafenib tosilate - carcinoma, hepatocellular; carcinoma, renal cell - daganatellenes szerek - hepatocellular carcinomasorafenib accord is indicated for the treatment of hepatocellular carcinoma (see section 5. renal cell carcinomasorafenib accord is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
sorafenib teva 200 mg filmtabletta
teva b.v. - sorafenib -
sorafenib sandoz 200 mg filmtabletta
sandoz hungária kft. - sorafenib tosylate -
sorafenib sandoz 400 mg filmtabletta
sandoz hungária kft. - sorafenib -
sorafenib g.l. pharma 200 mg filmtabletta
g.l. pharma gmbh - sorafenib tosylate -
sorafenib viatris 200 mg filmtabletta
viatris ltd. - sorafenib -
sorafenib pharmascience 200 mg filmtabletta
pharmascience international ltd. - sorafenib -
sorafenib stada 200 mg filmtabletta
stada arzneimittel ag - sorafenib tosylate -